Welcome to the dedicated Spotlight On Policy page, your central resource for curated, expert-driven coverage of pharmaceutical and health system policy across the United States, the United Kingdom, Europe, and the wider global landscape. US Policy updates News MSD claims two national priority vouchers; report The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates. News CDC signs off on advice ending universal hepatitis B jabs Overturning decades of advice, the CDC has said it no longer recommends that all US newborns receive a hepatitis B vaccine. News J&J claims FDA's latest national priority voucher The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma. Market Access The UK-US drug pricing deal: A welcome step, but not the fin... The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform more EU Policy updates R&D Europe has the tools to fight superbugs. Let’s use them. Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help. Market Access How are the US MFN and German MFG likely to impact pharmaceu... A comparison of the US MFN and German MFG. News Bayer gets EU approval for menopause drug Lynkuet Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer. News Approvals extend use of Roche, AbbVie drugs in lymphoma Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly. more UK Policy updates News Prof Jonathan Benger named as NICE's new CEO Prof Jonathan Benger will take over from Dr Sam Roberts as CEO of UK reimbursement authority NICE later this week, at a critical time for the agency. Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use. News UK confirms lower clawback rate for NHS medicines The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step." News Slow recruitment still hitting UK trials, says pharma Despite efforts to improve the environment for UK clinical trials, the sector is still facing headwinds like low recruitment rates and rising costs. more
News MSD claims two national priority vouchers; report The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
News CDC signs off on advice ending universal hepatitis B jabs Overturning decades of advice, the CDC has said it no longer recommends that all US newborns receive a hepatitis B vaccine.
News J&J claims FDA's latest national priority voucher The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.
Market Access The UK-US drug pricing deal: A welcome step, but not the fin... The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform
R&D Europe has the tools to fight superbugs. Let’s use them. Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.
Market Access How are the US MFN and German MFG likely to impact pharmaceu... A comparison of the US MFN and German MFG.
News Bayer gets EU approval for menopause drug Lynkuet Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.
News Approvals extend use of Roche, AbbVie drugs in lymphoma Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.
News Prof Jonathan Benger named as NICE's new CEO Prof Jonathan Benger will take over from Dr Sam Roberts as CEO of UK reimbursement authority NICE later this week, at a critical time for the agency.
Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
News UK confirms lower clawback rate for NHS medicines The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step."
News Slow recruitment still hitting UK trials, says pharma Despite efforts to improve the environment for UK clinical trials, the sector is still facing headwinds like low recruitment rates and rising costs.
